U.S. markets closed

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.20+0.19 (+3.79%)
At close: 4:00PM EDT
5.20 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close5.01
Open5.01
Bid4.97 x 800
Ask5.22 x 1800
Day's Range5.01 - 5.24
52 Week Range2.43 - 9.15
Volume231,927
Avg. Volume358,919
Market Cap236.122M
Beta (5Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Adamas Announces New Employment Inducement Grant
    Business Wire

    Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Jun 11, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the

  • New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease
    Business Wire

    New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease

    Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, "Effects of GOCOVRI® (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson’s disease and dyskinesia" in the peer-reviewed journal of Neurology and Therapy. The publication highlights a post-hoc da

  • Adamas to Present at Upcoming June Conferences
    Business Wire

    Adamas to Present at Upcoming June Conferences

    Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences: